1. Combination immunohistochemistry for CK5/6, p63, GATA6, and HNF4a predicts clinical outcome in treatment-naïve pancreatic ductal adenocarcinoma
- Author
-
Takahiro Shibayama, Akimasa Hayashi, Masao Toki, Keiichiro Kitahama, Yu-Jui Ho, Kenichiro Kato, Takahiro Yamada, Sho Kawamoto, Komei Kambayashi, Kazushige Ochiai, Koichi Gondo, Naohiro Okano, Jerry P. Melchor, Christine A. Iacobuzio-Donahue, Yoshihiro Sakamoto, Tadakazu Hisamatsu, and Junji Shibahara
- Subjects
Pancreatic ductal adenocarcinoma ,Expressional subtypes ,Surrogate biomarker ,Immunohistochemistry ,Medicine ,Science - Abstract
Abstract Although sequence-based studies show that basal-like features lead to worse prognosis and chemotherapy-resistance compared to the classical subtype in advanced pancreatic ductal adenocarcinoma (PDAC), a surrogate biomarker distinguishing between these subtypes in routine diagnostic practice remains to be identified. We aimed to evaluate the utility of immunohistochemistry (IHC) expression subtypes generated by unsupervised hierarchical clustering based on staining scores of four markers (CK5/6, p63, GATA6, HNF4a) applied to endoscopic ultrasound-guided fine needle aspiration biopsy (EUS-FNAB) materials. EUS-FNAB materials taken from 190 treatment-naïve advanced PDAC patients were analyzed, and three IHC patterns were established (Classical, Transitional, and Basal-like pattern). Basal-like pattern (high co-expression of CK5/6 and p63 with low expression of GATA6 and HNF4a) was significantly associated with squamous differentiation histology (p
- Published
- 2024
- Full Text
- View/download PDF